Reimer, Katharina Charlotte and Nadal, Jennifer and Meiselbach, Heike and Schmid, Matthias and Schultheiss, Ulla T. and Kotsis, Fruzsina and Stockmann, Helena and Friedrich, Nele and Nauck, Matthias and Krane, Vera and Eckardt, Kai-Uwe and Schneider, Markus P. and Kramann, Rafael and Floege, Juergen and Saritas, Turgay (2023) Association of mineral and bone biomarkers with adverse cardiovascular outcomes and mortality in the German Chronic Kidney Disease (GCKD) cohort. BONE RESEARCH, 11 (1): 52. ISSN 2095-4700, 2095-6231
Full text not available from this repository. (Request a copy)Abstract
Mineral and bone disorder (MBD) in chronic kidney disease (CKD) is tightly linked to cardiovascular disease (CVD). In this study, we aimed to compare the prognostic value of nine MBD biomarkers to determine those associated best with adverse cardiovascular (CV) outcomes and mortality. In 5 217 participants of the German CKD (GCKD) study enrolled with an estimated glomerular filtration rate (eGFR) between 30-60 mL<middle dot>min(-1) per 1.73 m(2) or overt proteinuria, serum osteoprotegerin (OPG), C-terminal fibroblast growth factor-23 (FGF23), intact parathyroid hormone (iPTH), bone alkaline phosphatase (BAP), cross-linked C-telopeptide of type 1 collagen (CTX1), procollagen 1 intact N-terminal propeptide (P1NP), phosphate, calcium, and 25-OH vitamin D were measured at baseline. Participants with missing values among these parameters (n = 971) were excluded, leaving a total of 4 246 participants for analysis. During a median follow-up of 6.5 years, 387 non-CV deaths, 173 CV deaths, 645 nonfatal major adverse CV events (MACEs) and 368 hospitalizations for congestive heart failure (CHF) were observed. OPG and FGF23 were associated with all outcomes, with the highest hazard ratios (HRs) for OPG. In the final Cox regression model, adjusted for CV risk factors, including kidney function and all other investigated biomarkers, each standard deviation increase in OPG was associated with non-CV death (HR 1.76, 95% CI: 1.35-2.30), CV death (HR 2.18, 95% CI: 1.50-3.16), MACE (HR 1.38, 95% CI: 1.12-1.71) and hospitalization for CHF (HR 2.05, 95% CI: 1.56-2.69). Out of the nine biomarkers examined, stratification based on serum OPG best identified the CKD patients who were at the highest risk for any adverse CV outcome and mortality.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | GROWTH-FACTOR 23; CIRCULATING OSTEOPROTEGERIN; ALKALINE-PHOSPHATASE; SERUM PHOSPHORUS; RISK; METAANALYSIS; MARKERS; EVENTS; CKD; CALCIFICATION; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Abteilung für Nephrologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 30 Jan 2024 12:13 |
| Last Modified: | 30 Jan 2024 12:13 |
| URI: | https://pred.uni-regensburg.de/id/eprint/60721 |
Actions (login required)
 |
View Item |
